9 research outputs found
GS-5759, a Bifunctional b 2 -Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells s
) and propranolol, were agonist-dependent, being significantly lower for GS-5759 than b2A. Collectively, these data can be explained by "forced proximity," bivalent binding where the pharmacophore in GS-5759 responsible for PDE4 inhibition also interacts with a nonallosteric domain within the b 2 -adrenoceptor that enhances the affinity of b2A for the orthosteric site. Microarray analyses revealed that, after 2-hour exposure, GS-5759 increased the expression of .3500 genes in BEAS-2B cells that were highly rank-order correlated with gene expression changes produced by indacaterol and GSK 256066 in combination (Ind/GSK). Moreover, the line of regression began close to the origin with a slope of 0.88, indicating that the magnitude of most gene expression changes produced by Ind/GSK was quantitatively replicated by GS-5759. Thus, GS-5759 is a novel compound exhibiting dual b 2 -adrenoceptor agonism and PDE4 inhibition with potential to interact on target tissues in a synergistic manner. Such polypharmacological behavior may be particularly effective in chronic obstructive pulmonary disease and other complex disorders where multiple processes interact to promote disease pathogenesis and progression
NEDD9 Is a Positive Regulator of Epithelial-Mesenchymal Transition and Promotes Invasion in Aggressive Breast Cancer
Epithelial to mesenchymal transition (EMT) plays an important role in many biological processes. The latest studies revealed that aggressive breast cancer, especially the triple-negative breast cancer (TNBC) subtype was frequently associated with apparent EMT, but the mechanisms are still unclear. NEDD9/HEF1/Cas-L is a member of the Cas protein family and was identified as a metastasis marker in multiple cancer types. In this study, we wished to discern the role of NEDD9 in breast cancer progression and to investigate the molecular mechanism by which NEDD9 regulates EMT and promotes invasion in triple-negative breast cancer. We showed that expression of NEDD9 was frequently upregulated in TNBC cell lines, and in aggressive breast tumors, especially in TNBC subtype. Knockdown of endogenous NEDD9 reduced the migration, invasion and proliferation of TNBC cells. Moreover, ectopic overexpression of NEDD9 in mammary epithelial cells led to a string of events including the trigger of EMT, activation of ERK signaling, increase of several EMT-inducing transcription factors and promotion of their interactions with the E-cadherin promoter. Data presented in this report contribute to the understanding of the mechanisms by which NEDD9 promotes EMT, and provide useful clues to the evaluation of the potential of NEDD9 as a responsive molecular target for TNBC chemotherapy
The In Vitro Pharmacology of GS-5759, A Novel Bifunctional Phosphodiesterase 4 Inhibitor and Long Acting β
Submillimeter-scale heterogeneity of labile phosphorus in sediments characterized by diffusive gradients in thin films and spatial analysis
Discovery of Orally Efficacious Phosphoinositide 3‑Kinase δ Inhibitors with Improved Metabolic Stability
Aberrant signaling of phosphoinositide
3-kinase δ (PI3Kδ)
has been implicated in numerous pathologies including hematological
malignancies and rheumatoid arthritis. Described in this manuscript
are the discovery, optimization, and in vivo evaluation of a novel
series of pyridine-containing PI3Kδ inhibitors. This work led
to the discovery of <b>35</b>, a highly selective inhibitor
of PI3Kδ which displays an excellent pharmacokinetic profile
and is efficacious in a rodent model of rheumatoid arthritis
2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors
Inhibition of phosphoinositide 3-kinase
δ (PI3Kδ) is
an appealing target for several hematological malignancies and inflammatory
diseases. Herein, we describe the discovery and optimization of a
series of propeller shaped PI3Kδ inhibitors comprising a novel
triaminopyrimidine hinge binder. Combinations of electronic and structural
strategies were employed to mitigate aldehyde oxidase mediated metabolism.
This medicinal chemistry effort culminated in the identification of <b>52</b>, a potent and highly selective inhibitor of PI3Kδ
that demonstrates efficacy in a rat model of arthritis
2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors
Inhibition of phosphoinositide 3-kinase
δ (PI3Kδ) is
an appealing target for several hematological malignancies and inflammatory
diseases. Herein, we describe the discovery and optimization of a
series of propeller shaped PI3Kδ inhibitors comprising a novel
triaminopyrimidine hinge binder. Combinations of electronic and structural
strategies were employed to mitigate aldehyde oxidase mediated metabolism.
This medicinal chemistry effort culminated in the identification of <b>52</b>, a potent and highly selective inhibitor of PI3Kδ
that demonstrates efficacy in a rat model of arthritis